Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 15, 2026 08:00 ET | Source: Andromeda Security

Andromeda Security Unveils the Industry’s Most Comprehensive Security Platform for Agentic AI, Delivering a Unified Solution for Humans, Agents, and NHIs

Andromeda Security unveils active AI access management, delivering real-time, resource-level enforcement and step-up JIT controls for autonomous agents.
June 03, 2026 07:00 ET | Source: JJP Biologics

JJP Biologics Announces Positive Interim Phase 1b Data for Nebaprubart (JJP-1212), an Anti-CD89 Antagonist, in Linear IgA Disease (LAD)

Favorable safety and tolerability profile, with rapid onset of clinical activity and therapeutic effects observed in patients with LADData support the start of a Phase 1b clinical trial in rheumatoid...
May 19, 2026 09:00 ET | Source: Orchid Security

Two-Thirds of Nonhuman Accounts Are Unseen and Unmanaged, According to New Identity Gap Report

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Orchid Security, the company solving identity at its core, today released its Identity Gap: 2026 Snapshot report, revealing that the majority of enterprise...
March 23, 2026 09:00 ET | Source: Galaxy Gaming, Inc.

Galaxy Gaming® Brings Iconic MONOPOLY® Magic To Table Games At IGA 2026

Galaxy Gaming will highlight its industry-leading portfolio of table games progressive systems at IGA 2026
March 18, 2026 09:00 ET | Source: Entro Security

Entro Launches Agentic Governance & Administration to Bring Visibility and Control to AI Access Across the Enterprise

BOSTON, March 18, 2026 (GLOBE NEWSWIRE) -- Entro Security, the enterprise security platform for Agentic AI & Non-Human Identities (NHI), today announced its Agentic Governance &...
January 07, 2026 07:00 ET | Source: JJP Biologics

JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...
January 07, 2026 01:00 ET | Source: JJP Biologics

JJP Biologics Announces Positive Top-Line Phase I Trial Results of JJP-1212, its anti-CD89 antagonist

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...
September 22, 2025 09:00 ET | Source: Orchid Security

Orchid Accelerates Identity Governance by Letting Applications Speak for Themselves

AUSTIN, Texas and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Orchid Security, the company bringing clarity and control to the complexity of enterprise identity, today announced landmark...
August 26, 2025 08:30 ET | Source: RSA America

RSA America Partners with IGA to Deliver Game-Changing Technology to Independent Grocers Nationwide

CHICAGO, Aug. 26, 2025 (GLOBE NEWSWIRE) -- RSA America, a leading digital transformation and innovative retail technology partner for grocers, today announced a strategic partnership with the...
June 25, 2025 08:00 ET | Source: CloudEagle AI

Report: 1 in 2 Employees Have Excessive Privileged Access—CloudEagle.ai Survey Warns of Escalating Insider Risk due to AI and SaaS Sprawl

CloudEagle.ai survey reveals 1 in 2 employees have excessive SaaS access, 60% of enterprise AI apps operate outside IT visibility, fueling insider risk.